Gilead’s stock is up about 4% after sharing new data for cancer drug

Shares of Gilead Sciences Inc. GILD, +5.16% were up 4.9% in trading on Monday after the company said in a news release that Trodelvy improved overall survival rates in people with HR+/HER2- metastatic...

Why These Analysts Are Bullish On Gilead’s Q1 Earnings

Morningstar Research Analyst Report: Gilead Sciences, Inc. Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV a...